Secondary oral squamous cell carcinoma following haematopoietic stem cell transplantation

Clin Exp Dermatol. 2024 Oct 24;49(11):1413-1419. doi: 10.1093/ced/llae157.

Abstract

We report the cases of 10 patients with oral squamous cell carcinoma (SCC) post-haematopoietic stem cell transplant (HSCT). Median latency from HSCT to oral SCC diagnosis was 10 years (range: 4-17 years), with 90% (9/10) reporting a history of chronic graft-versus-host disease (cGVHD) and 40% (4/10) exhibiting active severe manifestations of oral GvHD. Clinical findings at diagnosis included induration, ulceration, tenderness, bleeding, hyperkeratosis, speckling and lymphadenopathy. The tongue and buccal mucosa were the most common sites affected. The disease stage at presentation ranged from T1N0M0 to T4N2M0. Management included surgical resection in 90% (9/10) of patients with or without chemotherapy and/or radiotherapy. The median follow-up for the cohort was 1 year, with a 50% (5/10) mortality rate. SCC-specific mortality was 30% (3/10). Our data highlight the importance of regular, active oral and cutaneous surveillance of patients post-HSCT in specialized dermatology clinics, irrespective of GvHD severity and length of iatrogenic immunosuppression.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Squamous Cell* / etiology
  • Carcinoma, Squamous Cell* / pathology
  • Female
  • Graft vs Host Disease* / etiology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Mouth Neoplasms* / etiology
  • Mouth Neoplasms* / pathology
  • Mouth Neoplasms* / therapy
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / pathology
  • Young Adult